SCHEMBL7211679

SCHEMBL7211679

COC(=O)CC(NC(c1ccccc1)(c1ccccc1)c1ccccc1)N1C(=O)NC2(CCN(C(=O)O)CC2)C1=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CRBN Q96SW2 2/20 0.33
NPC1L1 Q9UHC9 1/20 0.33
OPRL1 P41146 1/20 0.32
CYP3A4 P08684 4/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
DDB1 Q16531 1/20 0.32
GAA P10253 1/20 0.32
GFER P55789 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP2C19 P33261 3/20 0.31
MAPK1 P28482 1/20 0.31
KCNA3 P22001 1/20 0.31
USP2 O75604 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7211500 0.80 CCR1 (0.41) CYP3A4CYP2D6CYP2C9MEN1KMT2A
SCHEMBL7562246 0.78 ITGB3 (0.33) TACR1L3MBTL1CRBNOPRL1DDB1
SCHEMBL7211673 0.77 TACR1 (0.41) TACR1OPRL1GAAMEN1KMT2A
SCHEMBL29045223 0.66 KMT2A (0.43) CYP2C9MEN1KMT2ACYP2C19HSD17B10
SCHEMBL5799829 0.66 KMT2A (0.43) CYP2C9MEN1KMT2ACYP2C19HSD17B10
SCHEMBL15672754 0.65 KCNN4 (0.43) CYP2D6KMT2A
SCHEMBL4857148 0.65 KCNN4 (0.43) CYP2D6KMT2A
SCHEMBL8996586 0.63 POLB (0.42) KMT2A
SCHEMBL8996547 0.63 POLB (0.42) KMT2A
SCHEMBL4847757 0.63 KCNA5 (0.44) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6620820-B2 Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies HOECHST AKTIENGESELLSCHAFT (DE) 2003-09-16 US disclosed
US-20020119999-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors HOECHST AKTIENGESELLSCHAFT 2002-08-29 US disclosed
US-20010021708-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors WEHNER VOLKMAR (DE) 2001-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021708-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors ADGRF1, CALCR, SOST TACR1 35/4885L3MBTL1 4642/4885CRBN 3910/4885
US-20020119999-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors ADGRF1, CALCR, SOST TACR1 35/4885L3MBTL1 4642/4885CRBN 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.